Affimed N.V.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Shawn Leland
- Full Time Employees
- 76
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Gottlieb-Daimler-Straße 2 Mannheim BW Germany 68165
- IPO Date
- Sep 12, 2014
- CIK
- 0001608390
- Website
- affimed.com
- Similar Companies
- Business
- Affimed N.V. is a clinical-stage biopharmaceutical company focused on developing innate cell engager (ICE®) immunotherapies to treat cancer, headquartered in Heidelberg, Germany, and operating primarily in the United States and Europe. Founded in 2000, the company leverages its ROCK® platform to design bispecific molecules that redirect innate immune cells, such as natural killer (NK) cells and macrophages, toward tumor targets. Core products and services include Acimtamig (AFM13), an ICE® targeting CD30 and CD16A for hematologic malignancies; AFM24, an EGFR-directed ICE® for solid tumors; internal ICE® platform development and collaborations to advance novel tetravalent, bispecific antibody candidates; and pipeline expansion through strategic partnerships and licensing arrangements. Affimed’s business model centers on clinical development and partnerships rather than product sales, with revenue generated from collaborations, milestone payments, and potential future licensing and commercialization agreements. Primary markets encompass hematologic cancers and solid tumors, with ongoing trials across global sites and functions spanning research, development, and prospective manufacturing and regulatory activities. The company’s latest corporate developments include new or expanded partnerships with pharma and biotech collaborators to advance combination therapies and broader ICE® utilization, ongoing trials in Phase 2 for AFM13 and AFM24, and continuous strategic reviews of pipeline priorities and cash runway to sustain clinical programs. Affimed operates with subsidiaries and affiliate relationships to support international research, development, and potential commercialization activities, maintaining governance and reporting through its public listing on NASDAQ under the ticker AFMD. This integrated profile reflects Affimed’s emphasis on empowering the innate immune system to combat cancer through its ICE® technologies and collaborative development model.
Affimed Announces Receipt of Nasdaq Delisting Notice
Affimed Announces Filing for the Opening of Insolvency Proceedings
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
Affimed N.V. (AFMD) Q3 2024 Earnings Call Transcript
Affimed Reports Third Quarter 2024 Financial Results & Business Update
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
Affimed to Present at the Cantor Global Healthcare Conference 2024
Affimed N.V. (AFMD) Q2 2024 Earnings Call Transcript
Affimed Reports Second Quarter 2024 Financial Results & Business Update
Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts